Syringe exchange programs prevented thousands of new HIV cases in Philadelphia, Baltimore

October 29, 2019

WASHINGTON, DC (Oct. 29, 2019) - Syringe exchange programs established in Philadelphia and Baltimore prevented a total of 12,483 new cases of HIV over a ten-year period, according to a study published today. The averted HIV infections also saved both cities millions of dollars every year, according to the researchers.

"Small investments in syringe exchange programs yield large savings in treatment costs," said Monica S. Ruiz, PhD, MPH, an associate professor in the Department of Prevention and Community Health at the George Washington University Milken Institute School of Public Health (Milken Institute SPH) and the principal investigator on the project. "Syringe exchange programs represent a powerful way to stop the spread of HIV, especially in communities struggling to fight the opioid epidemic. "

The new study, published in the Journal of Acquired Immune Deficiency Syndromes, may help policymakers nationwide understand the benefits of providing funding for syringe exchange programs. Such programs distribute sterile injection equipment to injection drug users and thus discourage the practice of sharing needles, which can spread HIV, the virus that causes AIDS.

Ruiz and her colleagues looked at how policy changes allowing for implementation of legal syringe exchange programs in Philadelphia and Baltimore affected the number of new HIV cases over a decade. The researchers used a mathematical modeling technique to estimate how many cases of HIV had been averted after the programs had been set up.

The researchers found that policies to allow syringe exchange programs to operate averted 10,592 new cases of HIV in Philadelphia and 1,891 new cases of HIV in Baltimore over a ten-year period.

Syringe exchange programs help some of the most vulnerable people in urban, suburban and rural communities avoid HIV infection - a risk associated with injection drug use. Both Philadelphia and Baltimore have seen a spike of new HIV cases associated with drugs, including heroin and other opioids.

This study showed that the averted HIV cases also saved each city money because most people who inject drugs are covered by public health insurance. Philadelphia saved an estimated $243 million every year due to the drop in new HIV cases - cases averted by syringe exchange. In Baltimore, the savings amounted to $62 million annually.

Ruiz and her colleagues also factored in the lifetime cost of treating someone with HIV and the expense associated with setting up a syringe exchange program. They found that the one-year return on investment was nearly $183 million for Philadelphia. For Baltimore, that same return on investment was estimated at about $47 million.

Policymakers and public health officials considering a syringe exchange program to reduce the threat posed by the opioid epidemic and HIV should take a hard look at the scientific results in this study and others. A 2015 study by Ruiz showed a syringe exchange program in the District of Columbia prevented 120 new cases of HIV and saved D.C. an estimated $44 million in just a two-year period.

"Giving injection drug users access to clean syringes can not only help them avoid HIV but often helps them obtain other health services, including access to drug treatment programs," Ruiz said. "Such programs offer communities huge public health and societal benefits, including a reduction in new HIV cases and cost savings to publicly funded HIV care."

The study, "Using Interrupted Time Series Analysis to Measure the Impact of Legalized Syringe Exchange on HIV Diagnoses in Baltimore and Philadelphia," was published as part of a supplement to the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
Funding for the research was provided by the National Institute on Drug Abuse, which is part of the National Institutes of Health.

This study was a collaboration between the Milken Institute SPH, the University of Pennsylvania Perelman School of Medicine, the Philadelphia Department of Public Health, Prevention Point Philadelphia, the Johns Hopkins Bloomberg School of Public Health and the Baltimore City Health Department.

George Washington University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to